Early detection and differential diagnosis of high-risk prostate cancer is imperative, so as to enable risk-stratification and decision-making in disease management. This research shows that the ECM oncoprotein Extradomain-B Fibronectin (EDB-FN) is strongly associated with high-risk prostate tumors and with low-risk prostate tumors that evolve into high-risk tumors, highlighting the potential of EDB-FN as a promising diagnostic biomarker for prostate cancer imaging. In addition, we have developed EDB-FN-specific peptide targeted MRI contrast agents that facilitate accurate differential detection and risk-stratification of prostate cancers.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords